The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Open accessAbstract
Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line of AR signaling inhibitors (ARSi). Experimental Design: Between March 2014 and April 2017, we recruited patients with mCRPC (n = 168) prior to ARSi in a cohort study encompassing 10 European centers. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumor cells (CTC) and circulating tumor DNA (ctDNA). Targeted CTC RNA sequencing (RNA-seq) allowed the detection of eight AR splice variants (ARV). Low-pass whole-genome and targeted gene-body sequencing of AR and TP53 was applied to identify amplifications, loss of heterozygosity, mutations, and structural rearrangements in ctDNA. Clinical or radiologic progression-free survival (PFS) was estimated by Kaplan–Meier analysis, and independent associations were determined using multivariable Cox regression models. Results: Overall, no single AR perturbation remained associated with adverse prognosis after multivariable analysis. Instead, tumor burden estimates (CTC counts, ctDNA fraction, and visceral metastases) were significantly associated with PFS. TP53 inactivation harbored independent prognostic value [HR 1.88; 95% confidence interval (CI), 1.18–3.00; P = 0.008], and outperformed ARV expression and detection of genomic AR alterations. Using Cox coefficient analysis of clinical parameters and TP53 status, we identified three prognostic groups with differing PFS estimates (median, 14.7 vs. 7.51 vs. 2.62 months; P < 0.0001), which was validated in an independent mCRPC cohort (n = 202) starting first-line ARSi (median, 14.3 vs. 6.39 vs. 2.23 months; P < 0.0001). Conclusions: In an all-comer cohort, tumor burden estimates and TP53 outperform any AR perturbation to infer prognosis. See related commentary by Rebello et al., p. 1699
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344 · cited 1×
“In addition, as the chemo-hormonal therapy landscape for mPC evolves (26-28), the somatic evolutionary trajectory of the AR-locus is likely to be altered and needs to be explored as guidelines are updated.”
BackgroundAndrogen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.027 · Cited by 268
Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173
Cited by
Genomics of lethal prostate cancer at diagnosis and castration resistance
Mateo, J., Seed, G., Bertan, C., Rescigno, P., Dolling, D., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Gurel, B., Clarke, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132031 · Cited by 313
Annala, M., Fu, S., Bacon, J. V. W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S. J., Lo, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.205 · Cited by 73
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers
Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23186 · Cited by 44
Maurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1341 · Cited by 14
Metadata
- Authors
- De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.-J., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., Brouwers, B., Lybaert, W., Everaert, E. G., De Maeseneer, D., Strijbos, M., Bols, A., Fransis, K., Beije, N., de Kruijff, I. E., van Dam, V., Brouwer, A., Goossens, D., Heyrman, L., Van den Eynden, G. G., Rutten, A., Del Favero, J., Rantalainen, M., Rajan, P., Sleijfer, S., Ullén, A., Yachnin, J., Grönberg, H., Van Laere, S. J., Lindberg, J., & Dirix, L. Y.
- Venue
- Clinical Cancer Research
- Published
- 2019-03-15
- Volume
- 25
- Issue
- 6
- Pages
- 1766-1773
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2892240038
- Cited by
- 174
- References
- 6
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1943
- The paper
- De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.-J., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., Brouwers, B., Lybaert, W., Everaert, E. G., De Maeseneer, D., Strijbos, M., Bols, A., Fransis, K., . . . Dirix, L. Y. (2019). TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.